Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
40.6M
-
Number of holders
-
144
-
Total 13F shares, excl. options
-
31.4M
-
Shares change
-
+6.29M
-
Total reported value, excl. options
-
$2.08B
-
Value change
-
+$419M
-
Put/Call ratio
-
0.72
-
Number of buys
-
92
-
Number of sells
-
-47
-
Price
-
$66.20
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q1 2024
160 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2024.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 144 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.4M shares
of 40.6M outstanding shares and own 77.25% of the company stock.
Largest 10 shareholders include FMR LLC (5.02M shares), BlackRock Inc. (2.17M shares), ALKEON CAPITAL MANAGEMENT LLC (1.6M shares), STATE STREET CORP (1.56M shares), VANGUARD GROUP INC (1.55M shares), Darwin Global Management, Ltd. (1.44M shares), ORBIMED ADVISORS LLC (1.27M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.22M shares), Point72 Asset Management, L.P. (972K shares), and TCG Crossover Management, LLC (879K shares).
This table shows the top 144 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.